ROQ vs. CIZ, FAB, HEMO, OBD, EVG, MTFB, DEST, GENF, BSFA, and VAL
Should you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include Cizzle Biotechnology (CIZ), Fusion Antibodies (FAB), Hemogenyx Pharmaceuticals (HEMO), Oxford BioDynamics (OBD), Evgen Pharma (EVG), Motif Bio (MTFB), Destiny Pharma (DEST), Genflow Biosciences (GENF), BSF Enterprise (BSFA), and ValiRx (VAL). These companies are all part of the "biotechnology" industry.
Roquefort Therapeutics vs. Its Competitors
Roquefort Therapeutics (LON:ROQ) and Cizzle Biotechnology (LON:CIZ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.
Roquefort Therapeutics has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500. Comparatively, Cizzle Biotechnology has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.
In the previous week, Cizzle Biotechnology had 2 more articles in the media than Roquefort Therapeutics. MarketBeat recorded 2 mentions for Cizzle Biotechnology and 0 mentions for Roquefort Therapeutics. Roquefort Therapeutics' average media sentiment score of 1.88 beat Cizzle Biotechnology's score of 0.36 indicating that Roquefort Therapeutics is being referred to more favorably in the media.
Cizzle Biotechnology has lower revenue, but higher earnings than Roquefort Therapeutics. Cizzle Biotechnology is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.
1.7% of Roquefort Therapeutics shares are owned by institutional investors. 60.4% of Roquefort Therapeutics shares are owned by company insiders. Comparatively, 43.7% of Cizzle Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Cizzle Biotechnology has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Cizzle Biotechnology's return on equity of -0.23% beat Roquefort Therapeutics' return on equity.
Summary
Roquefort Therapeutics and Cizzle Biotechnology tied by winning 6 of the 12 factors compared between the two stocks.
Get Roquefort Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roquefort Therapeutics Competitors List
Related Companies and Tools
This page (LON:ROQ) was last updated on 7/15/2025 by MarketBeat.com Staff
Free ROQ Stock Alerts